SELECT trial information
The double-blinded SELECT cardiovascular outcomes trial compared subcutaneous once-weekly semaglutide 2.4 mg with placebo as an adjunct to standard of care for prevention of major adverse cardiovascular (MACE) events over a period of up to 5 years. Read more about its background, methodology, results, and more.
Trial Rationale
Trial Rationale for the SELECT trial
Trial Design
Trial Design for the SELECT trial
Trial Objectives
Trial Objectives for the SELECT trial
Baseline Characteristics
Baseline Characteristics for the SELECT trial
Featured Insights and Resources
Trial Rationale
Trial Rationale for the SELECT trial
Additional Information
Speak to a live medical representative.
If you are a healthcare provider from the United States, click below to request information directly from the Novo Nordisk Medical Information department. If you are a patient, please visit here to contact us, or call 1-800-727-6500.
Search the Medical Information Database
The Scientific Exchange is a resource for U.S. Healthcare Professionals to learn more about disease states investigated by Novo Nordisk and our related products.
Scientific Exchange is a trademark of Novo Nordisk Health Care AG.
Novo Nordisk is a registered trademark of Novo Nordisk A/S.
Non-US Health Care Professionals, please go to www.novonordiskpro.com.
